MDWD
NASDAQ HealthcareMediWound Ltd. - Ordinary Shares
Biotechnology
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
๐ Market Data
| Price | $13.86 |
|---|---|
| Volume | 154,406 |
| Market Cap | 178.94M |
| Beta | 0.090 |
| RSI (14-Day) | 63.5 |
| 200-Day MA | $15.25 |
| 50-Day MA | $13.05 |
| 52-Week High | $19.70 |
| 52-Week Low | $11.80 |
| Forward P/E | -6.05 |
| Price / Book | 5.02 |
๐ฏ Investment Strategy Scores
MDWD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (65/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find MDWD in your text
Paste any article, transcript, or post โ the tool will extract MDWD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.